Clinical trials: Vomiting
Nausea and Vomiting, Chemotherapy-Induced
A Study to Assess the Safety and Interaction Between Casopitant and Ketoconazole When Taken By Healthy Adults
Casopitant may affect liver enzymes that metabolize ketoconazole. This study is designed to test the safety and the extent of the Casopitant affect on ketoconazole levels in healthy human subjects.
- Trial name
- NCT00460707
- Testing
- Casopitant 150 mg, Ketoconazole, Casopitant 50 mg
- Where
- 3 sites in United States
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Nausea With Vomiting Chemotherapy-Induced
Buccal Film Versus IV Injection Palonosetron for Moderately Emetogenic Chemotherapy Induced Nausea and Vomiting
Phase 2 study to compare efficacy, safety and PK of palonosetron, a long acting 5-HT3 receptor antagonist, by buccal film delivery compared to iv injection for chemotherapy induced nausea or vomiting (CINV).
- Trial name
- NCT04592198
- Testing
- Palonosetron Hydrochloride Buccal Film 0.25 Mg, Palonosetron Hydrochloride Buccal Film 0.5 Mg, Palonosetron Hydrochloride, 0.25 Mg/5 mL Intravenous Solution
- Where
- 7 sites in United States
- Volunteers
- 22 people
- Sponsor
- Xiamen LP Pharmaceutical Co., Ltd
Gastroparesis
Enterra Therapy Clinical Study (Gastric Stimulation for Gastroparesis)
This study is to evaluate the safety and effectiveness of gastric stimulation in the reduction of nausea and vomiting in patients with gastroparesis using an approved Humanitarian device.
- Trial name
- NCT00157755
- Testing
- Enterra Therapy
- Where
- 6 sites in United States
- Volunteers
- 87 people
- Sponsor
- MedtronicNeuro
Migraine, Pain
A Study to Assess the Efficacy and Safety of Oral CL-H1T in the Treatment of Acute Migraine Pain
A Study to Assess the Efficacy and Safety of Oral CL-H1T in the Treatment of Acute Migraine Pain.
- Conditions
- Migraine, Pain, Nausea, Vomiting
- Trial name
- NCT03877718
- Testing
- Arm 1: CL-H1T, Arm 2: CL-H1T, Arm 3: Sumatriptan Succinate 100 mg capsule
- Where
- 3 sites in United States
- Volunteers
- 475 people
- Sponsor
- Charleston Laboratories, Inc
Nausea and Vomiting of Pregnancy
The Efficacy Of Diclectin® For Nausea And Vomiting Of Pregnancy
The purpose of this study is to determine whether Diclectin® (doxylamine succinate USP 10 mg and pyridoxine HCl 10 mg) is more effective at controlling the nausea and vomiting of pregnancy than a placebo.
- Trial name
- NCT00614445
- Testing
- doxylamine succinate 10 mg/pyridoxine hydrochloride 10 mg
- Where
- 7 sites in United States
- Volunteers
- 280 people
- Sponsor
- Duchesnay Inc.
Chemotherapy Induced Nausea and Vomiting
Pharmacokinetics and Safety of Sancuso and IV Granisetron in Pediatrics Aged 6 to 12 Years
The purpose of this study is to determine the dosing strategy for adolescents aged 6 to 12 years.
- Trial name
- NCT01596413
- Testing
- Sancuso, IV granisetron
- Sponsor
- Kyowa Kirin Pharmaceutical Development Ltd
Pain, Nausea
A Study in Opioid-Experienced, Non-Dependent Recreational Drug Users to Determine the Abuse Potential and Safety of CL-108 Tablets Administered Via the Oral Route
The purpose of this study is to assess the abuse potential of CL-108 tablets, including the abuse deterrent effects of promethazine, following oral administration, relative to hydrocodone/acetaminophen (APAP) tablets and placebo…
- Conditions
- Pain, Nausea, Vomiting
- Trial name
- NCT02712554
- Testing
- CL-108, M366
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Charleston Laboratories, Inc
PONV
Phase IIIb Study of APD421 in Combination as PONV Prophylaxis
A comparison of the efficacy of APD421 and placebo when combined with a standard anti-emetic in the prevention of PONV in patients at high risk of Post-operative Nausea and Vomiting (PONV).
- Trial name
- NCT02337062
- Testing
- APD421
- Where
- 25 sites in United States, France and 1 more
- Volunteers
- 1,147 people
- Sponsor
- Acacia Pharma Ltd
Postoperative Nausea and Vomiting, Nausea and Vomiting, Postoperative
Study Of An NK-1 Anti-Emetic Medication For The Prevention Of Post-Operative Nausea And Vomiting In Female Patients
The purpose of this study is to determine the effectiveness of this medication in preventing nausea and vomiting in female patients at risk for post-operative nausea and vomiting (PONV).
- Trial name
- NCT00600990
- Testing
- GW597599
- Where
- 55 sites in United States, Australia and 10 more
- Volunteers
- 624 people
- Sponsor
- GlaxoSmithKline
Vomiting, Nausea
A Study of Ramosetron Plus DX, Dexamethasone, Compared to Granisetron Plus DX for the Prevention of Vomiting and Nausea
The purpose of this study is to compare the efficacy and safety of ramosetron plus dexamethasone injection with granisetron plus dexamethasone injection for the prevention of chemotherapy-induced vomiting and nausea.
- Trial name
- NCT00272285
- Testing
- Ramosetron, Granisetron
- Where
- 2 sites in Taiwan
- Volunteers
- 287 people
- Sponsor
- Astellas Pharma Inc
Chemotherapy-Induced Nausea and Vomiting
A Study to Assess the Bioequivalence of Aprepitant and Fosaprepitant and the Effect of Food on Aprepitant Bioavailability (0869-165)
This study will assess the bioequivalence of single oral doses of aprepitant (MK0869) to a single intravenous infusion of fosaprepitant (MK0517) and also determine the effect of food on the bioavailability of oral aprepitant.
- Trial name
- NCT00945321
- Testing
- aprepitant 165 mg, Comparator: aprepitant 185 mg, Comparator: fosaprepitant 150 mg
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Nausea and Vomiting Chemotherapy-Induced, Nausea Post Chemotherapy
Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC)
Chemotherapy often causes nausea and vomiting (CINV), and this is a major problem for the children being treated for cancer. To prevent this, a combination of two substances in fixed proportion (IV NEPA) was developed.
- Trial name
- NCT06904235
- Testing
- IV NEPA (fosnetupitant/palonosetron), Reference Treatment: IV ondansetron infusion, Reference Treatment: IV fosaprepitant infusion
- Where
- 20 sites in Greece, Poland and 2 more
- Volunteers
- 95 people
- Sponsor
- Helsinn Healthcare SA
Nausea, Vomiting
An Investigational Drug for the Prevention of Chemotherapy-Induced Nausea and Vomiting (MK-0869-071)
This protocol will study an investigational drug treatment plan against standard therapy in the prevention of chemotherapy-induced nausea and vomiting in patients diagnosed with breast cancer who are to be treated with up to 4…
- Conditions
- Nausea, Vomiting, Breast Neoplasms
- Trial name
- NCT00092183
- Testing
- MK0869, aprepitant / Duration of Treatment: 3 days, Comparator: ondansetron / Duration of Treatment: 3 days
- Volunteers
- 866 people
- Sponsor
- Merck Sharp & Dohme LLC
Nausea, Vomiting
A Single Dose, 4-Period, 2-Treatment Replicate Design Bioequivalency Study of Granisetron Hydrochloride 1 mg Tablets Under Fasting Conditions
The objective of this study was to assess bioequivalence of a potential generic 1 mg granisetron tablet formulation compared with Roche Laboratories' 1 mg granisetron tablet, Kytril, following a single 1 mg dose, under fasting…
- Trial name
- NCT00618254
- Testing
- Granisetron
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Roxane Laboratories
Postoperative Pain
Comparison of the Safety of Q8003 Versus Morphine Equivalent Doses of Its Components (Oxycodone and Morphine) in Bunionectomy Patients
This is a randomized, double-blind, multicenter, repeat-dose study of fixed doses of Q8003 12 mg/8 mg given q6hr compared to morphine sulfate 24 mg and oxycodone hydrochloride 16 mg given q6hr for the management of acute moderate…
- Trial name
- NCT01280331
- Testing
- Q8003 (morphine sulfate and oxycodone hydrochloride), Morphine sulfate, Oxycodone HCl
- Where
- 4 sites in United States
- Volunteers
- 375 people
- Sponsor
- QRxPharma Inc.
Nausea and Vomiting, Postoperative, Postoperative Nausea and Vomiting
Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women
This study is being conducted to see if adding GW679769 (casopitant) to ZOFRAN will significantly decrease the number of patients who experience nausea and vomiting after surgery.
- Trial name
- NCT00334152
- Testing
- casopitant
- Where
- 70 sites in United States, Belgium and 9 more
- Volunteers
- 515 people
- Sponsor
- GlaxoSmithKline
Chemotherapy Induced Nausea and Vomiting
Study of Chemotherapy and Patient Health Outcomes for Nausea and Emesis (0000-041)
The purpose of this study is to assess whether timely feedback to providers on patient experiences with delayed chemotherapy induced nausea and vomiting (CINV) lead to differences in patient outcomes for subsequent cycles.
- Trial name
- C-PHONE (NCT00211601)
- Testing
- Disease Management Assessment
- Volunteers
- 1,500 people
- Sponsor
- Merck Sharp & Dohme LLC
Healthy
Study in Healthy Males to Assess Distribution, Metabolism, and Excretion of Radio-labelled AZD9742 Administered as a 2-hour Infusion
The purpose of this study is to assess distribution, metabolism, and excretion of radio-labelled AZD9742 administered as a 2-hour infusion to healthy male volunteers.
- Trial name
- NCT01275781
- Testing
- [14C]-AZD9742
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- AstraZeneca
Nausea, Vomiting
To Demonstrate the Relative Bioavailability Study of Ondansetron HCl 24 mg Tablets Under Non-Fasting Conditions
To demonstrate the relative bioavailability study of Ondansetron HCl 24 mg tablets under non-fasting conditions.
- Trial name
- NCT00947128
- Testing
- Ondansetron HCl 24 mg Tablets (Sandoz, Inc.), Zofran (Ondansetron HCl) 24 mg Tablets (GlaxoSmithKline)
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Sandoz
Postoperative Nausea and Vomiting
A Randomized Controlled Study of Rolapitant for the Prevention of Nausea and Vomiting Following Surgery (Study P04937AM1)(COMPLETED)
This is a multicenter, randomized, controlled study in women who are having elective open abdominal surgery with general anesthesia and who are expected to need patient-controlled analgesia (PCA) after surgery.
- Trial name
- NCT00539721
- Testing
- Rolapitant Dose 1, Rolapitant Dose 2, Rolapitant Dose 3
- Volunteers
- 619 people
- Sponsor
- Merck Sharp & Dohme LLC